Fig. 2

Receiver operating characteristic (ROC) curve of the baseline sIgE/sIgG4 ratio of Der p (a) and Der p 1 (b) as predictive parameters of clinical responsiveness, and the correlation between baseline sIgE/sIgG4 ratio for Der p 1 and clinical improvement rate for TCS at 52-weeks of AIT (c). AIT, allergen immunotherapy